abstract |
The present invention relates to a combination comprising (a) a synaptic vesicle protein 2a (“SV2A”) ligand selected from the group consisting of levetiracetam, brivaracetam and seletracetam; and (b) a positive allosteric modulator of the metabotropic glutamatergic receptor subtype 2 selected from a compound having a Formula as shown in the abstract drawing or a pharmaceutically acceptable salt or a solvate thereof. |